133 related articles for article (PubMed ID: 38112426)
1. Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (
Mutti M; Cordella S; Parisotto A; Bettelli F; Morselli M; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Giusti D; Colaci E; Cassanelli L; Paolini A; Martinelli S; Maffei R; Riva G; Nasillo V; Sarti M; Trenti T; Comoli P; Tagliafico E; Manfredini R; Eccher A; Lagreca I; Barozzi P; Potenza L; Marasca R; Candoni A; Luppi M; Forghieri F
Leuk Lymphoma; 2024 Apr; 65(4):511-515. PubMed ID: 38112426
[No Abstract] [Full Text] [Related]
2. Nucleophosmin mutation in de-novo acute myeloid leukemia.
Rastogi P; Naseem S; Varma N; Varma S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
[TBL] [Abstract][Full Text] [Related]
3. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Ma W; Kantarjian H; Zhang X; Jilani I; Sheikholeslami MR; Donahue AC; Ravandi F; Estey E; O'Brien S; Keating M; Giles FJ; Albitar M
Cancer Biomark; 2009; 5(1):51-8. PubMed ID: 19242062
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
Jeziskova I; Razga F; Toskova M; Dvorakova D; Timilsina S; Mayer J; Racil Z
Leuk Lymphoma; 2013 Apr; 54(4):867-70. PubMed ID: 22950897
[No Abstract] [Full Text] [Related]
5. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Lesieur A; Thomas X; Nibourel O; Boissel N; Fenwarth L; De Botton S; Fournier E; Celli-Lebras K; Raffoux E; Recher C; Lambert J; Berthon C; Pigneux A; Itzykson R; Turlure P; Pautas C; Vargaftig J; Preudhomme C; Dombret H; Duployez N
Haematologica; 2021 Jun; 106(6):1767-1769. PubMed ID: 33299234
[TBL] [Abstract][Full Text] [Related]
6. NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.
Raman HS; Shanmugam V; Li J; Steensma DP; Kim AS; Luskin MR
Leuk Lymphoma; 2021 Jul; 62(7):1790-1792. PubMed ID: 33586600
[No Abstract] [Full Text] [Related]
7. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
8. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
11. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
Liso A; Castiglione F; Cappuccio A; Stracci F; Schlenk RF; Amadori S; Thiede C; Schnittger S; Valk PJ; Döhner K; Martelli MF; Schaich M; Krauter J; Ganser A; Martelli MP; Bolli N; Löwenberg B; Haferlach T; Ehninger G; Mandelli F; Döhner H; Michor F; Falini B
Haematologica; 2008 Aug; 93(8):1219-26. PubMed ID: 18603563
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies.
Wertheim G; Bagg A
J Mol Diagn; 2008 May; 10(3):198-202. PubMed ID: 18403611
[TBL] [Abstract][Full Text] [Related]
13. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
[TBL] [Abstract][Full Text] [Related]
14. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.
Boonthimat C; Thongnoppakhun W; Auewarakul CU
Haematologica; 2008 Oct; 93(10):1565-9. PubMed ID: 18641025
[TBL] [Abstract][Full Text] [Related]
15. A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis.
Woolthuis CM; Mulder AB; Verkaik-Schakel RN; Rosati S; Diepstra A; van den Berg E; Schuringa JJ; Vellenga E; Kluin PM; Huls G
Haematologica; 2013 Oct; 98(10):1532-8. PubMed ID: 23716555
[TBL] [Abstract][Full Text] [Related]
16. More than ten percent of relapses occur after five years in AML patients with
Bertoli S; Tavitian S; Bérard E; Mansat-De Mas V; Largeaud L; Gadaud N; Rieu JB; Vergez F; Luquet I; Huguet F; Sarry A; Delabesse E; Récher C
Leuk Lymphoma; 2020 May; 61(5):1226-1229. PubMed ID: 32022605
[No Abstract] [Full Text] [Related]
17. Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia.
Pazhakh V; Zaker F; Alimoghaddam K; Atashrazm F
Ann Saudi Med; 2011; 31(1):45-50. PubMed ID: 21245599
[TBL] [Abstract][Full Text] [Related]
18. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
19. NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.
Patel SS
Pathobiology; 2024; 91(1):18-29. PubMed ID: 36944324
[TBL] [Abstract][Full Text] [Related]
20. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
